Tony Berberabe, MPH, is the Editor for Targeted Therapies in Oncology. Berberabe received his Bachelor of Arts in Biology from Rutgers University and his Master of Public Health from the University of Medicine and Dentistry in New Jersey.
Emerging Therapies in CML Undergo Investigation in Chronic-Phase Illness
October 7th 2020Today’s patients diagnosed with chronic myeloid leukemia can look forward to a near-normal life expectancy, provided they have good access to treatment and monitoring and are properly managed, said Jorge Cortes, MD.
An Abundance of Targets Span the GI Malignancies Setting
October 6th 2020With the number of targets in gastrointestinal cancer growing, particularly KRAS in colorectal cancer and tumor mutational burden across all gastrointestinal tumors, Andrea Cercek, MD, sought to provide an overview of current and emerging targets during the 17th Annual Meeting of the International Society of Gastrointestinal Oncology.
SIRT Administered With Nivolumab Demonstrates Positive Safety, Tolerability Results in HCC
October 3rd 2020Findings from the NASIR-HCC phase 2 clinical trial demonstrated the safety and tolerability of nivolumab administered with selective internal radiation therapy containing yttrium-90 resin in patients who were ineligible for transarterial chemoembolization.
Stage Is Set for Exploring TNBC, HER2-Positive Settings at 38th Annual CFS
September 23rd 2020Delivering evidence-based state-of-the art cancer care in the management of hematologic and solid malignancies is the mainstay of the 38th Annual CFS®: Innovative Cancer Therapy for Tomorrow conference taking place virtually November 4 through 6, 2020.
No PFS Improvement Is Seen With EGFR/VEGF Inhibitor Combo
September 20th 2020Patients with advanced lung adenocarcinoma who harbor EGFR T790M mutations did not experience significant progression-free survival improvement with osimertinib plus bevacizumab versus osimertinib alone, according to findings presented by Yukihiro Toi, MD, during the 2020 European Society for Medical Oncology Virtual Congress.
Sequencing Immunotherapy After Encorafenib and Binimetinib Showed Higher PFS in Metastatic Melanoma
September 19th 2020The use of encorafenib and binimetinib followed by immunotherapy demonstrated a higher progression-free survival, as well as an objective response rate and median PFS at 1 and 2 years that were consistent with those reported in pivotal studies, according to a presentation by Paolo Ascierto, MD, at the 2020 ESMO Virtual Congress.
Lanreotide Autogel Dosed More Frequently Delays More Toxic Regimens in Pancreatic, Midgut NETs
September 19th 2020For patients with progressive pancreatic or midgut neuroendocrine tumors, improvements in disease-free survival and progression-free survival were seen when the dosing of lanreotide Autogel was increased from 120 mg every 28 days to every 14 days. Data from the phase 2 CLARINET FORTE study suggest that this treatment option can delay switching to a more toxic treatment, which was presented at the 2020 ESMO Virtual Congress.
Daratumumab Leads to Deep Responses Among Newly Diagnosed Black Patients With Multiple Myeloma
September 10th 2020Adding the anti-CD38 antibody, daratumumab, to the standard of care regimen of lenalidomide, bortezomib, and dexamethasone, improved depth of response, stringent complete response , and minimal residual disease negativity, in a subgroup of Black patients who had newly diagnosed multiple myeloma, according to findings presented at the eighth annual Society of Hematologic Oncology meeting.
ISGIO Conference Explores Enhancing Fellows’ Experience, Ramifications of MSI-High Phenotype
August 15th 2020As the new chair of the 17th Annual International Society of Gastrointestinal Oncology meeting, Tanios Bekaii-Saab, MD, said that this year’s virtual conference will place particular emphasis on fellows’ education and involvement.
Comorbid Toxicities Can Cloud Differential Diagnosis for Immune-Related AEs
June 29th 2020A review of selected trials looking at frequencies of grade 3 irAEs suggests that renal and bone marrow toxicities occur more frequently with the use of PD-1 and PD-L1 inhibitors compared with agents blocking CTLA-4
Statistical Analyses Confirm Benefit of Cabazitaxel Over Abiraterone or Enzalutamide in mCRPC
May 31st 2020Stratified multivariate analysis as well as efficacy from multiple treatment time points confirmed the benefit of cabazitaxel over abiraterone acetate or enzalutamide as a standard treatment in men with metastatic castration-resistant prostate cancer who were previously treated with docetaxel and either of those 2 androgen receptor-targeted agents, according to results presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program.
Deep and Durable Responses Still Observed With JNJ-4528 in Relapsed/Refractory Myeloma
May 29th 2020According to the lead study author Jesus G. Berdeja, MD, the overall response rate was 100%, with a stringent complete response rate of 86%. Further, the progression-free survival rate was 86% at 9 months.
Atezolizumab Plus Axi-Cel Leads to Manageable Safety Profile in DLBCL
April 29th 2020A manageable safety profile was demonstrated with the combination of atezolizumab plus an anti-CD19 chimeric antigen receptor T-Cell therapy in patients with refractory diffuse large B-cell lymphoma in the ZUMA-6 trial.
Capmatinib Generates Clinically Meaningful Activity in MET Exon 14-Mutated NSCLC
April 28th 2020Deep and durable responses were observed in 97 patients with advanced non–small cell lung cancer harboring a MET exon 14 mutation with treatment of capmatinib, according to GEOMETRY mono-1 study, presented at the 2020 American Association for Cancer Research Annual Meeting.
Nintedanib Shows Significant Benefit in PFS, OS in Muscle-Invasive Bladder Cancer
April 9th 2020Investigators found no difference in the primary end point of pathologic complete response between the 2 arms of a trial evaluating gemcitabine and cisplatin plus either nintedanib or placebo in muscle-invasive bladder cancer; however; secondary end points of progression-free survival and overall survival demonstrated significant benefit in patients who got nintedanib.
Darolutamide Trial Evaluates Noninferiority to Standard Care in Intermediate-Risk Prostate Cancer
April 6th 2020External Beam Radiation therapy with or without androgen deprivation therapy or surgery are the standards of care for men with intermediate-risk prostate cancer, but the adverse events associated with the treatments, delayed testosterone recovery and prolonged erectile dysfunction, are challenges.
Myeloma Cochair Expects Interactive Interplay for Hematologic Conference
March 31st 2020The upcoming 4th Annual Medical Crossfire Hematologic Malignancies, hosted by Physicians’ Education Resource, LLC, promises a lively exchange between experts in multiple myeloma, leukemia, and lymphoma and physician attendees who are on the front lines of patient care. This educational format moves away from didactic lectures and instead focuses on discussions on scientific advances and their impact on real-world patient cases.
Liquid Biopsy Reveals Differences in DDR Genes in Prostate Cancer
March 27th 2020Liquid biopsy results that identify DNA damage repair genes in prostate cancer may be a useful tool in clinical-deci­sion making, espe­cially because these genes can elucidate therapeutic vulnera­bilities that could be exploited by current treatments.
Selinexor Triplet Shows Improved PFS in Multiple Myeloma Over Standard Therapy
March 3rd 2020The triplet combination of selinexor, bortezomib, and dexamethasone demonstrated an improved median progression-free survival rate over the standard regimen of bortezomib and dexamethasone in treating patients with multiple myeloma in the BOSTON trial
FDA Approves Supplemental NDA for Neratinib in Metastatic HER2-Positive Breast Cancer
February 27th 2020The FDA has approved a supplemental New Drug Application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have previously received 2 or more anti–HER2-based regimens in the metastatic setting, according to a press release issued by the manufacturer Puma Biotechnology, Inc.